Journal of global antimicrobial resistance最新文献

{"title":"Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus of diverse genetic types","authors":"Marisa L. Winkler,&nbsp;John H. Kimbrough,&nbsp;Helio S. Sader,&nbsp;Mariana Castanheira,&nbsp;Rodrigo E. Mendes","doi":"10.1016/j.jgar.2025.07.022","DOIUrl":"10.1016/j.jgar.2025.07.022","url":null,"abstract":"<div><h3>Background</h3><div>Ceftobiprole was approved by the United States (US) Food and Drug Administration (FDA) in 2024 and by the European Medicines Agency in 2013 for the treatment of pneumonia, bacterial skin and skin structure infections, and <em>Staphylococcus aureus</em> bloodstream infections. Numerous methicillin-resistant <em>S. aureus</em> (MRSA) lineages have been identified with unique assemblages of resistance determinants and virulence factors.</div></div><div><h3>Methods</h3><div>MRSA isolates (<em>n</em> = 150) were collected from bloodstream infections in 2018–2019. Broth microdilution antimicrobial susceptibility testing was performed, and results were interpreted by US FDA, Clinical and Laboratory Standards Institute, and European Committee on Antimicrobial Susceptibility Testing guidelines. Genome sequencing was performed to determine multi-locus sequence, clonal complex (CC), <em>spa</em>, and SCC<em>mec</em> types; typing results were used to determine clonal group.</div></div><div><h3>Results</h3><div>Overall, 97.3% of isolates were ceftobiprole susceptible by FDA and European Committee on Antimicrobial Susceptibility Testing criteria compared to 85.3% for ceftaroline, 73.3%–74.0% for clindamycin, 94.7% for trimethoprim-sulfamethoxazole, and 100.0% for linezolid, vancomycin, and daptomycin. More than 90% of isolates were CC5, CC8, or CC22, and ceftobiprole inhibited 97.7%, 98.3%, and 94.1% of these isolates, respectively, compared to 84.1%, 91.5%, and 70.6% activity of ceftaroline. Only 4 (2.7%) ceftobiprole non-susceptible isolates were identified compared to 22 (14.7%) non-susceptible to ceftaroline; all non-susceptible isolates were from clonal groups within CC8 (USA500 (Lyon) and Hungarian/Brazilian), CC5 (USA100 (Swiss) and USA100), or CC22 (UK-EMRSA-15).</div></div><div><h3>Conclusions</h3><div>Ceftobiprole demonstrated higher activity than ceftaroline against a phylogenetically diverse set of MRSA isolates and may represent a preferred broad-spectrum antimicrobial choice for the treatment of MRSA infections.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 323-331"},"PeriodicalIF":3.2,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic insights into multidrug-resistant Enterobacter hormaechei isolates from seafood at retail carrying the mcr-9 gene and other resistance determinants on IncHI2 plasmids","authors":"Valeria Michelacci ,&nbsp;Silvia Pieralisi ,&nbsp;Elisa Albini ,&nbsp;Francesca Romana Massacci ,&nbsp;Gabriele Angelico ,&nbsp;Paola Chiani ,&nbsp;Manuela Marra ,&nbsp;Maria Carollo ,&nbsp;Chiara Francesca Magistrali ,&nbsp;Francesca Leoni","doi":"10.1016/j.jgar.2025.07.019","DOIUrl":"10.1016/j.jgar.2025.07.019","url":null,"abstract":"<div><h3>Objectives</h3><div>We aimed to characterise the genomic features of two multidrug-resistant (MDR) isolates from retail seafood samples.</div></div><div><h3>Methods</h3><div>Antimicrobial susceptibility was determined by minimum inhibitory concentration (MIC) tests. Genome sequences were obtained by hybrid sequences of short and long.</div></div><div><h3>Results</h3><div>The two MDR (ampicillin, cefotaxime, ciprofloxacin, ceftazidime, nalidixic acid, gentamicin, tetracycline, sulfamethoxazole, cefoxitin, and trimethoprim) <em>Enterobacter hormaechei</em> (<em>E. hormaechei</em>) isolates belonged to ST114. Nineteen antibiotic resistance genes (ARGs), including <em>mcr-9</em>, were identified in the genomes. The <em>mcr-9</em> and other resistance determinants were on an IncHI2 plasmid. Sequence analysis showed mutations in genes implicated in colistin resistance, of which a non-conservative one was present in the <em>qseB</em>. Virulence genes of T6SS or involved in motility were identified in both genomes. Comparison of <em>mcr-9</em> plasmids allowed us to identify similar plasmids in the isolates from Italy and in the five best hits of the PLSDB database, with some regions of difference in the MDR region. A genome cluster analysis grouped our isolates into the same clade of ST114 <em>E. hormaechei</em> isolated from humans in Guadeloupe in 2018 and Switzerland in 2019, most of which harboured an IncHI2 replicon but not the <em>mcr-9</em> gene.</div></div><div><h3>Conclusions</h3><div>The finding of MDR <em>E. hormaechei</em> in seafood, carrying the <em>mcr-9</em> and other resistance determinants on IncHI2 plasmids, enhances our understanding of antimicrobial resistance (AMR) and highlights the importance of gaining more data on the occurrence and circulation of AMR and ARGs in aquatic environments, in order to better understand sources, transmission routes, and evolution of AMR mechanisms.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 394-397"},"PeriodicalIF":3.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First report of regional spreading and long-term inhabitation of VanD-type vancomycin-resistant Enterococcus faecalis clinical strains: A proposal of new classification of vanD gene subtypes","authors":"Kensuke Mimura ,&nbsp;Yusuke Hashimoto ,&nbsp;Jun Kurushima ,&nbsp;Hidetada Hirakawa ,&nbsp;Takahiro Nomura ,&nbsp;Koichi Tanimoto ,&nbsp;Tetsuro Muratani ,&nbsp;Daisuke Todokoro ,&nbsp;Hideo Akiyama ,&nbsp;Haruyoshi Tomita","doi":"10.1016/j.jgar.2025.07.021","DOIUrl":"10.1016/j.jgar.2025.07.021","url":null,"abstract":"<div><h3>Objective</h3><div>VanD-type vancomycin resistance is rarely reported in <em>Enterococcus faecalis</em>. This study aimed to characterise five VanD-type vancomycin-resistant <em>E. faecalis</em> strains isolated over 8 years from three hospitals in a local city in Japan, with a focus on resistance mechanisms, genetic background, and phylogenetic classification.</div></div><div><h3>Methods</h3><div>Five <em>E. faecalis</em> strains (SVR2085, SVR2281, SVR2330, SVR2331, and SVR2332) were analysed using antimicrobial susceptibility testing, plasmid profiling, and whole-genome sequencing. Genomic islands (GIs) containing <em>vanD</em> gene clusters were characterised. Core GI gene and core genome phylogenies were compared, and <em>vanD</em> homologues were classified using public database sequences.</div></div><div><h3>Results</h3><div>All strains exhibited high-level resistance to vancomycin (MIC &gt;1024–64 mg/L), multiple drug resistance, and carried pheromone-responsive plasmids encoding bacteriocin 41 as a colonisation factor. Four strains shared nearly identical GIs (126–185 kbp), while SVR2330 had a structurally distinct GI. Phylogenetic analysis showed that the four similar strains formed a single cluster, suggesting a common ancestor, whereas SVR2330 was divergent. Comparative analysis of 37 <em>vanD</em> homologues revealed high genetic diversity, allowing classification into three subgroups – <em>vanD(I), vanD(II)</em>, and <em>vanD(III)</em>. The <em>vanD</em> of SVR2330 was assigned as <em>vanD(III)-4</em>, and the others as <em>vanD(II)-6, -11, -15</em>, and -<em>17</em>.</div></div><div><h3>Conclusions</h3><div>This study proposes a new classification scheme for diverse <em>vanD</em> genes and provides the first evidence of the regional spread and long-term persistence of VanD-type vancomycin-resistant <em>E. faecalis</em> in Japan.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 398-410"},"PeriodicalIF":3.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activity of LpxC inhibitors on carbapenemase-producing Citrobacter spp. clinical isolates","authors":"Víctor Vinuesa ,&nbsp;Raquel Cruces ,&nbsp;Javier E. Cañada-García ,&nbsp;Jesús Oteo-Iglesias ,&nbsp;Andrés Corral-Lugo ,&nbsp;Michael J. McConnell","doi":"10.1016/j.jgar.2025.07.020","DOIUrl":"10.1016/j.jgar.2025.07.020","url":null,"abstract":"<div><h3>Objective</h3><div><em>Citrobacter</em> spp. are commonly found in the human intestine and can cause antibiotic-resistant infections. Inhibitors of LpxC, an enzyme involved in the synthesis of lipid A, have demonstrated potent activity against multiple Gram-negative species, but their activity in <em>Citrobacter</em> spp. has not been well-characterised. The objective of the present study was to evaluate the antimicrobial activity of LpxC inhibitors against carbapenemase-producing <em>Citrobacter</em> spp. clinical isolates.</div></div><div><h3>Methods</h3><div>The MICs of LpxC-2, LpxC-4, and CHIR-090 LpxC inhibitors were determined for 61 clinical isolates with high genetic diversity. Time-kill assays with the three LpxC inhibitors were performed with two <em>Citrobacter</em> spp. strains, with low (Cit 52) and high (Cit 110) LpxC inhibitor MIC values.</div></div><div><h3>Results</h3><div>LpxC-4 was shown to be the most potent inhibitor (MIC₉₀ = 0.5 mg/L). In general, the three LpxC inhibitors demonstrated similar activity between <em>Citrobacter</em> spp. isolates harbouring type A (<em>n</em> = 11 isolates), B (<em>n</em> = 39 isolates), and D (<em>n</em> = 11 isolates) carbapenemases. All LpxC inhibitors showed bactericidal activity at concentrations 4× the MIC and no activity at ¼× the MIC at 24 h for the two <em>Citrobacter</em> spp. strains analysed.</div></div><div><h3>Conclusions</h3><div>Although LpxC-4 had a lower MIC₉₀ value compared with CHIR-090, CHIR-090 showed a bactericidal effect at short times and prevented the regrowth of both isolates in the time-kill assays. In terms of cross-resistance, all three structurally similar LpxC inhibitors showed a moderate positive correlation between their activity.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 366-370"},"PeriodicalIF":3.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global prevalence of tuberculosis and drug-resistant forms: A 30-year analysis from 1990 to 2019","authors":"Xiaoying Lv ,&nbsp;Xiuyuan Ji ,&nbsp;Leiqun Xiong ,&nbsp;Yongquan Chen ,&nbsp;Houzhao Wang ,&nbsp;Ying Yang","doi":"10.1016/j.jgar.2025.07.012","DOIUrl":"10.1016/j.jgar.2025.07.012","url":null,"abstract":"<div><h3>Objectives</h3><div>Tuberculosis (TB) remains a major global health threat. Multidrug-resistant (MDRTB) and extensively drug-resistant TB (XDRTB) present growing challenges. This study aims to analyze the global and national prevalence trends of TB and its subtypes from 1990 to 2019.</div></div><div><h3>Methods</h3><div>This study utilised Global Burden of Disease data to analyse age-standardised prevalence rates (ASPR) and evaluate the global and national prevalence trends of TB and its subtypes from 1990 to 2019.</div></div><div><h3>Results</h3><div>Global TB prevalence is declining but MDRTB and XDRTB are rising sharply. In 2019, TB ASPR was 23 085 per 100 000, falling 1.044% annually since 1990. Latent TB infection decreased 1.044% yearly to 22 906 per 100 000 in 2019. Drug-susceptible TB fell 1.692% annually to 169 per 100 000 in 2019. MDRTB rose 6.008% yearly, reaching 8.6 per 100 000 in 2019. XDRTB increased 71.746% yearly to 0.4 per 100 000. Rates varied widely between countries. ASPR tended to be higher in males and poorer regions. Pace of change differed by sex, socioeconomics and geography.</div></div><div><h3>Conclusions</h3><div>Substantial variations exist in TB prevalence and trends globally, reflecting inequities. Findings provide comprehensive long-term TB assessments, with rising multidrug resistance threatening progress and elimination goals. Urgent targeted strategies are needed for high-risk groups, surveillance, resources, commitment and political will, especially in disadvantaged populations.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 411-419"},"PeriodicalIF":3.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative in vitro activities of eravacycline and tigecycline against carbapenem-resistant Acinetobacter baumannii: Insights from whole genome sequencing analysis","authors":"Yang Zhong ,&nbsp;Jocelyn Qi Min Teo ,&nbsp;Hong Yi Chang ,&nbsp;Jiahao Yeo ,&nbsp;Shuhua Thong ,&nbsp;Sihui Tan ,&nbsp;Nurhayati Binte Monhamed Yusoff ,&nbsp;Tze Peng Lim ,&nbsp;Andrea Lay Hoon Kwa","doi":"10.1016/j.jgar.2025.06.021","DOIUrl":"10.1016/j.jgar.2025.06.021","url":null,"abstract":"<div><h3>Objectives</h3><div>Eravacycline (ERV), a novel tetracycline-class antibiotic, has demonstrated efficacy against carbapenem-resistant <em>Acinetobacter baumannii</em> (CRAB) in Europe and the United States but has not been evaluated in Singapore. The objectives of this study are to evaluate the activity of ERV against CRAB clinical isolates from Singapore and to investigate the genetic profiles of these isolates, exploring novel potential ERV resistance mechanisms through whole genome sequencing (WGS) analysis.</div></div><div><h3>Methods</h3><div>Three hundred CRAB clinical isolates collected from Singapore General Hospital (SGH) between 2012 and 2021 were tested for their susceptibility to ERV and other antibiotics. The genomic profile, including sequence type (ST), antimicrobial resistance, and virulence factor (VF) genes of these isolates, was determined. Isolates exhibiting high ERV minimum inhibitory concentrations (MICs) were further analysed to identify potential genetic mutations associated with reducing ERV susceptibility.</div></div><div><h3>Results</h3><div>ERV demonstrated strong in vitro activity against CRAB, with an MIC₉₀ of 2 µg/mL. WGS analysis revealed that the 300 CRAB isolates belonged to 23 STs, with ST2 being the predominant population and frequently harbouring intrinsic <em>bla</em>_OXA-type β-lactamases and tetracycline-class efflux pumps (<em>tet(B)</em>)<em>.</em> VF analysis shows extensive genetic diversity, with variations beyond simple presence/absence patterns. Notably, the emergence of ERV resistance (elevated MIC, and MIC &gt; MIC₉₀) was detected, and genetic analysis of high-MIC isolates identified novel mutations in the resistance-nodulation-cell division (RND) efflux pump genes (<em>adeABC, adeFGH</em>, and <em>adeIJK</em>) and their regulatory elements (<em>adeS/R</em> and <em>adeL/N</em>).</div></div><div><h3>Conclusions</h3><div>ERV is a promising therapeutic option for managing CRAB infections in Singapore. However, the emergence of resistance mediated by novel genetic mutations highlights the need for continuous surveillance and further investigation.</div><div>© 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 340-346"},"PeriodicalIF":3.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A timeline of reckoning: Tracking the historical rise of antimicrobial resistance across HIV, TB, and malaria","authors":"Tayla Williamson ,&nbsp;Jack Adderley ,&nbsp;Kylie Quinn ,&nbsp;Taane G. Clark ,&nbsp;Sharon R. Lewin ,&nbsp;Christian Doerig","doi":"10.1016/j.jgar.2025.07.014","DOIUrl":"10.1016/j.jgar.2025.07.014","url":null,"abstract":"<div><div>Antimicrobial resistance is one of the major health challenges of this century. Here, we provide an in-depth perspective on the evolution of antimicrobial resistance in three globally relevant infectious diseases, HIV, tuberculosis (TB), and malaria. Specifically, we scrutinize the timelines between deployment and the subsequent emergence of resistance for all drugs that have been mobilized in the fight against these three diseases. Our data reveals that malaria exhibits a slower rate of resistance development to monotherapies in comparison to HIV and TB. While the adoption of combination therapies significantly reduces the risk of <em>de novo</em> emergence of resistance, the challenge of pre-existing drug resistance persists, necessitating continuous surveillance and emphasizing the critical need for diverse and innovative approaches to manage and mitigate the ever-growing threat of antimicrobial resistance.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 420-431"},"PeriodicalIF":3.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged infusion of β-lactam antibiotics decreases short-term mortality in critically ill patients: A meta-analysis and trial sequential analysis from randomized control trials","authors":"Baofang Liang ,&nbsp;Jianwei Su ,&nbsp;Ya Wang ,&nbsp;Linxin Chen ,&nbsp;Yuanchun Mo ,&nbsp;Baocheng Xie","doi":"10.1016/j.jgar.2025.07.016","DOIUrl":"10.1016/j.jgar.2025.07.016","url":null,"abstract":"<div><h3>Objectives</h3><div>The aim of this study was to ascertain the clinical efficacy of prolonged infusion of β-lactam antibiotics in critically ill patients and to provide additional evidence.</div></div><div><h3>Methods</h3><div>This meta-analysis was prospectively registered on the PROSPERO database (CRD42024614894). We searched PubMed, Web of Science, Scopus, and Clinical Trials.gov to identify eligible randomized control trials (RCTs) for conducting a meta-analysis and trial sequential analysis (TSA) comparing mortality between prolonged vs. intermittent infusion of β-lactam antibiotics in adult critically ill patients. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used to evaluate the certainty of evidence for all outcomes.</div></div><div><h3>Results</h3><div>Twenty-four RCTs involving 9558 adult critically ill patients were finally included in this meta-analysis. Compared with intermittent infusion of β-lactam antibiotics, the pooled results demonstrated that prolonged infusion was associated with lower short-term mortality (OR = 0.87, 95% confidence interval [CI] = 0.79–0.95; high certainty), but not 90-d mortality statistically (OR = 0.91, 95% CI = 0.83–1.01; moderate certainty), which was supported by TSA. Regression analysis found no significant factors affecting short-term mortality. For other outcomes, prolonged infusion could significantly improve clinical cure (OR = 1.31, 95% CI = 1.20–1.42; low certainty) and microbiological eradication (OR = 2.29, 95% CI = 1.61–3.25; moderate certainty).</div></div><div><h3>Conclusions</h3><div>Despite no benefit in 90-d mortality statistically, prolonged infusion of β-lactam antibiotics was associated with significant benefits in short-term mortality, clinical cure, and microbiological eradication. TSA supported the short-term survival benefit of prolonged infusion in critically ill patients.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 356-365"},"PeriodicalIF":3.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of a new transposon, Tn7772, on a novel plasmid from multidrug-resistant Escherichia coli in China","authors":"Yong Pan ,&nbsp;Ting Li ,&nbsp;Yanan Zhang ,&nbsp;Qiufan Xu ,&nbsp;Li Yang ,&nbsp;Yuanfeng Zhao ,&nbsp;Jinge Xu","doi":"10.1016/j.jgar.2025.07.010","DOIUrl":"10.1016/j.jgar.2025.07.010","url":null,"abstract":"<div><h3>Background</h3><div>The emergence of multidrug-resistant (MDR) <em>Escherichia coli</em> causes a serious threat to human and animal health. To characterize the genetic environments of a novel plasmid pQL57EC-1 in an MDR <em>E. coli</em> strain QL57EC from feces of a healthy swine in China.</div></div><div><h3>Methods</h3><div>The plasmid pQL57EC-1 was characterized by antimicrobial susceptibility testing, whole genome sequencing and bioinformatic analysis. The transferability of pQL57EC-1 was verified by conjugation experiments and transformation experiments.</div></div><div><h3>Results</h3><div><em>E. coli</em> QL57EC carries two plasmids. pQL57EC-1 belongs to the incompatibility groups IncF-FIB/IncX1, while plasmid pQL57EC-2 belongs to the incompatibility group IncF-FIB. Notably, pQL57EC-1 was a novel plasmid, containing a novel Tn7772 transposon flanked by two copies of IS26 at both ends, which can also be found on plasmids from <em>Salmonella enterica</em> isolated from human feces. Conjugation assays for <em>E. coli</em> QL57EC were unsuccessful. However, pQL57EC-1 could be transferred into <em>E. coli</em> DH5α by transformation experiments.</div></div><div><h3>Conclusions</h3><div>This study reported a novel plasmid pQL57EC-1 harboring a novel Tn7772 transposon from swine derived <em>E. coli</em> QL57EC.This finding suggests that Tn7772 may pose a threat to both human and animal health by acting as a reservoir for antibiotic resistance genes (ARGs) and facilitating cross-species transmission.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 332-339"},"PeriodicalIF":3.2,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging epidemic of the predominant clusters of FC428-like Neisseria gonorrhoeae in Guangdong, China","authors":"Yang Chen ,&nbsp;Xiao-lin Qin ,&nbsp;Han Zhou ,&nbsp;Xing-zhong Wu ,&nbsp;Wen-tao Chen ,&nbsp;Zi-yan Zhang ,&nbsp;Qing-xian Zhan ,&nbsp;Zhan-qin Feng ,&nbsp;Yao-hua Xue ,&nbsp;Yong-fei Hu ,&nbsp;Chi-xing Guo ,&nbsp;Feng Wang ,&nbsp;Ming Li ,&nbsp;Zhi-zhou Wu ,&nbsp;Jian-hong Xie ,&nbsp;Lian-hui Liang ,&nbsp;Hui-xuan Xiao ,&nbsp;Zheng-qi Shi ,&nbsp;Xue-mei Hu ,&nbsp;Qian Li ,&nbsp;He-Ping Zheng","doi":"10.1016/j.jgar.2025.07.005","DOIUrl":"10.1016/j.jgar.2025.07.005","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to investigate the molecular characteristics of predominant epidemic clusters of FC428-like <em>N. gonorrhoeae</em> in Guangdong, China in 2022.</div></div><div><h3>Methods</h3><div>Minimum inhibitory concentrations (MICs) were determined for <em>N. gonorrhoeae</em> isolates collected from the Guangdong Gonococcal Antimicrobial Surveillance Program. <em>N. gonorrhoeae</em> multiantigen sequence typing (NG-MAST), antimicrobial resistance sequence typing (NG-STAR), multilocus sequence typing (MLST) sequence types (STs), and <em>penA</em> alleles were determined by whole-genome sequencing. The isolates were further characterised by phylogenetic analysis.</div></div><div><h3>Results</h3><div>A total of 537 <em>N. gonorrhoeae</em> isolates were analysed, molecular analysis revealed that 7.8% of the isolates carried <em>penA</em> 60.001 allele, which was highly resistant to ceftriaxone (88.1%) and cefixime (100.0%). The predominant STs in <em>penA</em> 60.001 isolates were MLST ST1903 (23,54.8%), ST7365 (11,26.2%), NG-STAR ST1143 (13,31.0%), ST233 (4,9.5%), ST1133 (4,9.5%), and NG-MAST ST22261 (10,23.8%). Among 537 isolates, of which 11.2% were resistant to ceftriaxone and 19.6% to cefixime. In western Guangdong, resistance to ceftriaxone and cefixime reached 17.3% and 26.9%, respectively. The most predominant types among ceftriaxone-resistant isolates are genetically closer to FC428 isolates, and differ from those among cefixime-resistant isolates. Phylogenetic analysis revealed that the Guangdong FC428-like isolates from 2021 to 2022 spread across the whole phylogenetic tree, but the majority were clustered within a distinct evolutionary clade.</div></div><div><h3>Conclusions</h3><div>FC428-like isolates in Guangdong formed a unique evolutionary clade with high cephalosporin resistance. These findings highlight the need to revise national gonorrhea treatment guidelines and prioritise the development of new antimicrobials.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"44 ","pages":"Pages 287-296"},"PeriodicalIF":3.2,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}